Previous 10 | Next 10 |
home / stock / ipsey / ipsey articles
Ipsen SA (OTC:IPSEF) (OTC:IPSEY) announced Monday that the U.S. Food and Drug Administration (FDA) had granted accelerated approval for Iqirvo (ela...
Ipsen's Iqirvo® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Ch...
PARIS, FRANCE, 2 May 2024 - Ipsen ((Euronext: IPN, OTC:IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointmen...
Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages ...
PARIS, FRANCE, 7 December 2023 - Ipsen ((Euronext: IPN, OTC:IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital M...
ELATIVE® Phase III trial confirms potential for investigational elafibranor as a novel, first-in-class, dual PPAR ?,? agonist for patients...
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("d...
PARIS, FRANCE, 4 September 2023 – Ipsen ((Euronext: IPN, OTC:IPSEY) announced today the co-optation of Pascal Touchon to its Board as an indepen...
PARIS, FRANCE, 1 September 2023 – Ipsen ((Euronext: IPN, OTC:IPSEY), a global specialty-driven biopharmaceutical company, announced today the ...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...